Table 1.
Baseline characteristics at enrollment of individuals with advanced prostate cancer in IRONMAN, by marital status and living arrangement (N=2,119)
| MARRIED | NOT MARRIED | |||||
|---|---|---|---|---|---|---|
| Living alone (n = 20) | Not living alone (n = 1647) | Total (n = 1667) | Living alone (n = 317) | Not living alone (n = 135) | Total (n = 452) | |
| Age, years (median, IQR) | 73.5 (68.0 – 78.0) | 71.0 (65.0 – 76.0) | 71.0 (65.0 – 76.0) | 70.0 (64.0 – 77.0) | 69.0 (62.5 – 75.5) | 70.0 (63.0 – 76.0) |
| Disease state, n (%) | ||||||
| mHSPC | 14 (70) | 1077 (65) | 1091 (65) | 216 (68) | 94 (70) | 310 (69) |
| CRPC | 6 (30) | 570 (35) | 576 (35) | 101 (32) | 41 (30) | 142 (31) |
| Continent of enrollment, n (%) | ||||||
| North America | 8 (40) | 766 (46) | 774 (46) | 143 (45) | 59 (44) | 202 (45) |
| Europe | 10 (50) | 670 (41) | 680 (41) | 140 (44) | 55 (41) | 195 (43) |
| Other | 2 (10) | 211 (13) | 213 (13) | 34 (11) | 21 (16) | 55 (12) |
| Race, n (%) | ||||||
| White | 14 (70) | 1319 (80) | 1333 (80) | 259 (82) | 94 (70) | 353 (78) |
| Non-white | 6 (30) | 328 (20) | 334 (20) | 58 (18) | 41 (30) | 99 (22) |
| Employment status, n (%) | ||||||
| Not working/Retired | 15 (75) | 1185 (72) | 1200 (72) | 227 (72) | 98 (73) | 325 (72) |
| Currently working | 5 (25) | 462 (28) | 467 (28) | 90 (28) | 37 (27) | 127 (28) |
| Smoking status, n (%) | ||||||
| Non-smokers | 17 (85) | 1501 (91) | 1518 (91) | 1269 (85) | 113 (84) | 382 (85) |
| Current smokers | 3 (15) | 146 (9) | 149 (9) | 48 (15) | 22 (16) | 70 (15) |
| Family history of prostate cancer, n (%) | ||||||
| No | 18 (90) | 1318 (80) | 1336 (80) | 261 (82) | 114 (84) | 375 (83) |
| Yes | 2 (10) | 329 (20) | 331 (20) | 56 (18) | 21 (16) | 77 (17) |
| PSA, ng/ml (median, IQR) | 6.0 (2.9 – 31.1) | 5.4 (1.0 – 23.0) | 5.4 (1.0 – 23.0) | 8.6 (1.6 – 45.0) | 5.9 (0.8 – 26.5) | 7.3 (1.4 – 41.5) |
| Education level, n (%) a | ||||||
| Less than some college | 10 (56) | 732 (50) | 742 (50) | 167 (58) | 79 (63) | 246 (59) |
| Some college or more | 8 (44) | 744 (50) | 752 (50) | 123 (42) | 47 (37) | 170 (41) |
| Missing | 2 | 171 | 173 | 27 | 9 | 36 |
| Gleason Score, n (%) a | ||||||
| 6 or less | 1 (7) | 62 (4) | 63 (4) | 12 (5) | 3 (3) | 15 (4) |
| 7 | 5 (33) | 380 (26) | 385 (26) | 88 (33) | 36 (32) | 124 (33) |
| 8 | 3 (20) | 283 (20) | 286 (20) | 38 (14) | 20 (18) | 58 (15) |
| 9–10 | 6 (40) | 713 (50) | 719 (49) | 125 (48) | 53 (47) | 178 (47) |
| Missing | 5 | 209 | 214 | 54 | 23 | 77 |
| ECOG performance status, n (%) a | ||||||
| 0 | 12 (63%) | 838 (56%) | 850 (56%) | 152 (53%) | 57 (48%) | 209 (51%) |
| 1 | 5 (26%) | 541 (36%) | 546 (36%) | 114 (40%) | 51 (43%) | 165 (41%) |
| 2 | 2 (11%) | 79 (5%) | 81 (5%) | 19 (7%) | 10 (8%) | 29 (7%) |
| 3 | 0 (0%) | 32 (2%) | 32 (2%) | 2 (1%) | 1 (1%) | 3 (1%) |
| 4 | 0 (0%) | 4 (0%) | 4 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Missing | 1 | 153 | 154 | 30 | 16 | 46 |
Abbreviations: IRONMAN, International Registry for Men with Advanced Prostate Cancer; IQR, Interquartile range; mHSPC, Metastatic hormone-sensitive prostate cancer; CRPC, Castration resistant prostate cancer; PSA, Prostate specific antigen; ECOG, Eastern Cooperative Oncology Group.
a
Among those with non-missing data.